Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federico Cappuzzo

Showing results (111-120 of 275) with videos related to

Pageof 28
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 22, 2011
Inherited germline T790M mutation and somatic epidermal growth factor receptor mutations in non-small cell lung cancer patientsCarmelo Tibaldi, Elisa Giovannetti, Enrico Vasile, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2011
Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancerWolfram Brugger, Nadja Triller, Maria Blasinska-Morawiec, et al.
Journal of Thoracic Disease|August 3, 2018
How to optimize the treatment strategy for patients with EGFR-mutant stage IA lung adenocarcinoma: an international multidisciplinary teamYalei Zhang, Jianfei Shen, Charles B Simone, et al.
Critical Reviews in Oncology/Hematology|December 4, 2020
Palliative- and non-palliative indications for glucocorticoids use in course of immune-checkpoint inhibition. Current evidence and future perspectivesDaniele Marinelli, Raffaele Giusti, Marco Mazzotta, et al.
The Breast Journal|March 7, 2021
COVID-19 risk in breast cancer patients receiving CDK4/6 inhibitors: literature data and a monocentric experienceMaddalena Barba, Eriseld Krasniqi, Laura Pizzuti, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 7, 2012
p95HER2 truncated form in resected non-small cell lung cancerFederico Cappuzzo, Yong Gon Cho, Andrea Sacconi, et al.
Science Signaling|January 19, 2017
The neuropilin 2 isoform NRP2b uniquely supports TGFβ-mediated progression in lung cancerRobert M Gemmill, Patrick Nasarre, Joyce Nair-Menon, et al.
The Lancet. Oncology|May 25, 2010
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 studyFederico Cappuzzo, Tudor Ciuleanu, Lilia Stelmakh, et al.
Future Oncology (London, England)|May 30, 2023
TROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLCBenjamin P Levy, Enriqueta Felip, Martin Reck, et al.
Journal of Clinical Medicine|April 23, 2022
Oncological Outcomes of Robotic Lobectomy and Radical Lymphadenectomy for Early-Stage Non-Small Cell Lung CancerFilippo Tommaso Gallina, Riccardo Tajè, Daniele Forcella, et al.
Pageof 28

Showing results (111-120 of 275) with videos related to

Sort By:
Pageof 28
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 22, 2011
Inherited germline T790M mutation and somatic epidermal growth factor receptor mutations in non-small cell lung cancer patientsCarmelo Tibaldi, Elisa Giovannetti, Enrico Vasile, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2011
Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancerWolfram Brugger, Nadja Triller, Maria Blasinska-Morawiec, et al.
Journal of Thoracic Disease|August 3, 2018
How to optimize the treatment strategy for patients with EGFR-mutant stage IA lung adenocarcinoma: an international multidisciplinary teamYalei Zhang, Jianfei Shen, Charles B Simone, et al.
Critical Reviews in Oncology/Hematology|December 4, 2020
Palliative- and non-palliative indications for glucocorticoids use in course of immune-checkpoint inhibition. Current evidence and future perspectivesDaniele Marinelli, Raffaele Giusti, Marco Mazzotta, et al.
The Breast Journal|March 7, 2021
COVID-19 risk in breast cancer patients receiving CDK4/6 inhibitors: literature data and a monocentric experienceMaddalena Barba, Eriseld Krasniqi, Laura Pizzuti, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 7, 2012
p95HER2 truncated form in resected non-small cell lung cancerFederico Cappuzzo, Yong Gon Cho, Andrea Sacconi, et al.
Science Signaling|January 19, 2017
The neuropilin 2 isoform NRP2b uniquely supports TGFβ-mediated progression in lung cancerRobert M Gemmill, Patrick Nasarre, Joyce Nair-Menon, et al.
The Lancet. Oncology|May 25, 2010
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 studyFederico Cappuzzo, Tudor Ciuleanu, Lilia Stelmakh, et al.
Future Oncology (London, England)|May 30, 2023
TROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLCBenjamin P Levy, Enriqueta Felip, Martin Reck, et al.
Journal of Clinical Medicine|April 23, 2022
Oncological Outcomes of Robotic Lobectomy and Radical Lymphadenectomy for Early-Stage Non-Small Cell Lung CancerFilippo Tommaso Gallina, Riccardo Tajè, Daniele Forcella, et al.
Pageof 28